About: Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients
Creator	Bernhard, David Doppler, Stefan Süßner, Susanne Wechselberger, Christian
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Serological assays for the determination of the immune status of patients that have tested positive for infection with SARS-CoV-2 by RT-PCR are required for, e.g., contact tracing and epidemiological studies. However, data concerning the performance parameters of commercially available high-throughput ELISA tests are still not available on a large scale. STUDY DESIGN: In our study, we have evaluated an in-house developed ELISA for the detection of the immunoglobulin classes A, G and M directed against the full-length spike glycoprotein from SARS-CoV-2. For this analysis, we have included 110 sera from patients presenting with COVID-19 symptoms or blood donors without symptoms collected at the Austrian Red Cross, Blood Transfusion Service for Upper Austria, Linz. In addition, we have selected four commercially available IgG-based ELISAs as well as one IgA/IgG-based ELISA for the detection of SARS-CoV-2 antigens as well as a multiplexed IgG-based micro-ELISA assay developed for rapid Point of Care testing applications. CONCLUSIONS: All assays evaluated in the course of this study demonstrated suitable sensitivity and specificity values for the identification of patients that have experienced a past infection with SARS-CoV-2. However, testing for the presence of additional immunoglobulins (IgA and IgM) as well as using combinations of different viral antigens is highly advised to improve the predictive values of serological assays.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104589
bibo:pmid	32810840
has license	no-cc
sha1sum (hex)	6b5feeb5fcd9f88e43d6f25840fee8371b72e483
schema:url	https://doi.org/10.1016/j.jcv.2020.104589
resource representing a document's title	Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients
has PubMed Central identifier	PMC7417972
has PubMed identifier	32810840
schema:publication	J Clin Virol
resource representing a document's body	covid:6b5feeb5fcd9f88e43d6f25840fee8371b72e483#body_text
is schema:about of	named entity 'assays' named entity 'patients' named entity 'tests' named entity 'However' named entity 'immunoglobulin' named entity 'determine' named entity 'immune status' named entity 'SARS-CoV-2' named entity 'SARS' named entity 'Performance evaluation' named entity 'epidemiological studies' named entity 'SARS-CoV-2' named entity 'POC' named entity 'rapid test' named entity 'antibodies' named entity 'IgG' named entity 'serological' named entity 'IgM' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'immune response' named entity 'virus' named entity 'infection' named entity 'sensitivity and specificity' named entity 'diagnostic test' named entity 'serum samples' named entity 'SARS-CoV-2' named entity 'Chinese province' named entity 'serological' named entity 'infection' named entity 'viral antigens' named entity 'Blood Transfusion' named entity 'false positive results' named entity 'antigen' named entity 'seroprevalence' named entity 'blood donors' named entity 'SARS-CoV-2' named entity 'IgG antibody' named entity 'denaturation' named entity 'antigens' named entity 'immune response' named entity 'immunoglobulin' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'viral antigens' named entity 'antigens' named entity 'IgG' named entity 'immunoglobulins' named entity 'immunoglobulins' named entity 'IgA' named entity 'Austrian Red Cross' named entity 'IgG antibodies' named entity 'serum samples' named entity 'antigens' named entity 'immunoglobulin' named entity 'immunoglobulins' named entity 'RT-PCR test' named entity 'respiratory disease' named entity 'POC' named entity 'Upper Austria' named entity 'convalescent plasma' named entity 'acute infection' named entity 'immunoglobulin' named entity 'diagnostic tests' named entity 'IgM' named entity 'immunoglobulins' named entity 'antibodies' named entity 'Germany' named entity 'Point of Care' named entity 'IgG' named entity 'causative agent' named entity 'immunoglobulin' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'RT-PCR' named entity 'SARS-CoV-2' named entity 'median age' named entity 'antigen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software